ONMD News & Events

OneMedNet announced a strategic collaboration with Navidence to help research organizations transform rapidly expanding healthcare data into clear, actionable real-world evidence. Pharmaceutical companies face growing pressure to integrate high-quality RWD for regulatory submissions, post-market surveillance, and AI model training. Navidence's platform enables precise definition of health data needs via Computable Operational Definitions-standardized, executable queries that translate complex study criteria into consistent, computable form across datasets. This collaboration integrates Navidence's CODefs with the OneMedNet iRWD platform powered by Palantir Foundry. This collaboration is intended to directly advance OneMedNet's life sciences strategy by addressing core industry demands of faster, more precise and usable data for pharmaceutical and CRO customers, along with expanded opportunities in the rapidly growing RWD market enabling access to precisely defined, fit for purpose datasets across Drug development and Life sciences research; AI model training and validation Health economics and outcomes research; Regulatory-grade evidence generation; and Value-based healthcare analytics

OneMedNet Corporation announced the next phase of commercial launch with its RWD Platform powered by Palantir Foundry. Following the November 10, 2025, demonstration of live feeds, subscription access, and AI-driven search at major tradeshows, the Company is actively converting customer evaluations into commercial subscriptions. Early results highlight superior performance, speed and analytical depth, reinforcing OneMedNet's position for life sciences and healthcare organizations generating real-world evidence. This launch drives rapid expansion of subscription contracts, including multi-year deals representing millions in incremental recurring revenue, with adoption growing across life sciences, AI Health Innovators. As the OneMedNet iRWD network scales-with over 2,130 healthcare sites and expanding multimodal data-subscription value rises through greater scale, diversity, real-time access, depth, and insight speed. Customer feedback from evaluations since Fall 2025 confirms the platform's strengths: unmatched analytical depth across integrated clinical/longitudinal datasets; accelerated cohort feasibility and discovery; streamlined intuitive workflows; and faster onboarding of diverse data partners.

OneMedNet Corporation announced a strategic partnership with ViuHealth. This partnership expands OneMedNet's autoimmune clinical ontology, to the OneMedNet iRWD platform. Under the agreement, ViuHealth will provide ongoing, longitudinal autoimmune disease data, strengthening OneMedNet's portfolio of high-value specialty datasets and supporting research, AI model development, HEOR initiatives, and regulatory-aligned use cases.

OneMedNet Corporation announced a strategic data licensing agreement with Risorius. This new relationship supports OneMedNet's continued focus on expanding its base of subscription contracts, adding multi-year agreements that represent millions of dollars in incremental recurring revenue. Under the agreement, Risorius has licensed access to large-scale electroencephalography and polysomnography waveform data paired with clinically meaningful context and longitudinal follow-up. The datasets will support internal R&D, model development, and validation efforts, including the advancement of EEG-based digital biomarkers and an AI Co-Scientist platform designed to support neurological and psychiatric clinical studies, especially for pharmaceutical companies and academic hospitals.